Kodiak posts Phase 3 wins; NeOnc gets FDA meeting; DataMeds launches GLP‑1 app; KNOREX rolls out AI amid listing risk
AI Summary
Kodiak Sciences (KOD) reported positive pivotal Phase 3 DAYBREAK results for Zenkuda—non‑inferior to aflibercept on vision (p=0.0007), 54% of patients reached 24‑week dosing at one year and 0% intraocular inflammation—and plans a multi‑indication BLA in Q4 2026 while other late‑stage readouts (tabirafusp‑ted ALTO, KSI‑101) remain pending. NeOnc (NTHI) set an FDA End‑of‑Phase‑1 Type B meeting for NEO212 on Nov 17, 2026 after early Phase‑1 signals and a recommended Phase‑2 dose of 610 mg, and also reported a positive NEO100 Phase‑2a PFS/OS readout; DataMeds (MEDS) launched a consumer GLP‑1 telehealth/pharmacy/wearables app with NFL Alumni/Corexa partnerships; KNOREX (KNRX) is deploying conversational AI campaign tools but faces an NYSE American noncompliance notice over stockholders’ equity. Timing: The press release does not indicate dilution today. Earliest dilution: date unknown.
Positives
- Kodiak (KOD) reported positive pivotal Phase 3 DAYBREAK results for Zenkuda and plans a multi‑indication BLA in Q4 2026
- NeOnc (NTHI) scheduled an FDA End‑of‑Phase‑1 Type B meeting for NEO212 (Nov 17, 2026) and reported a positive NEO100 Phase‑2a PFS/OS signal
- DataMeds (MEDS) launched the 'Health Lives Here' consumer app integrating telehealth, pharmacy and wearables with NFL Alumni/Corexa partnerships
Negatives
- NeOnc's Phase‑1 efficacy observations are exploratory and from small, non‑powered cohorts, requiring larger trials to validate
- KNOREX (KNRX) has an NYSE American notice for continued‑listing noncompliance tied to stockholders' equity
- Key DataMeds features (Long COVID/cancer focus, diagnostics, expanded provider network, digital‑twin) remain under development, creating execution risk
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: date unknown
Dilution status
delayed
Dilution timing
Dilution status: Delayed